ArticleInfectious diseases of poverty2025
Enhancing regional disease burden estimates: insights from the comparison of Global Burden of Disease and China's notifiable infectious diseases data with policy implications (2010-2020).
Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spatiotemporal heterogeneity and socioeconomic determinants of syphilis incidence in Xining, Northwest China: a geospatial analysis.BMC infectious diseases · 2026Article
- Using a novel hybrid AI-based paper-to-digital pipeline for extracting patient-level clinical data from routine hospital records in Kenya: a retrospective multicentre study.BMJ digital health & AI · 2026Article
- Current status of knowledge on the prevention of common infectious diseases among urban and rural populations: a cross-sectional study.Frontiers in public health · 2026Article
- Global burden and cross-country inequalities in rabies from 1990 to 2021: a systemic analysis of the global burden of disease study 2021.BMC infectious diseases · 2025Article
- From data to action: addressing geographic inequalities in rabies burden through targeted policies.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe Global Burden of Disease (GBD) study offers influential Disability-Adjusted Life Years (DALYs) estimates for various diseases. However, discrepancies with national surveillance data raise concerns about accuracy. This study aims to promote the deep integration of the GBD model with localized data and facilitate the development of region-specific models.
methodsData for 14 notifiable infectious diseases (NIDs), grouped into intestinal infectious diseases, respiratory infectious diseases, and sexually transmitted and blood-borne infections, were obtained from the Data-center of China Public Health Science. DALYs based on national surveillance data (2010-2020) were calculated using DALY formulas, and discrepancies with GBD estimates were quantified through ratio comparisons. A historical timeline map highlighted key infectious disease control policies and certified disease elimination events in China.
resultsNational surveillance data show a decrease in DALYs for 14 NIDs in China, from 6,529,124.62 person-years in 2010 to 6,326,497.18 person-years in 2020. Among them, sexually transmitted and blood-borne infections have the highest burden, with 78% of DALYs attributed to hepatitis B (4,864,028.29 person-years). Respiratory infectious diseases follow, with 99% of DALYs from TB (394,927.70 person-years). Intestinal infectious diseases have the relative lightest burden, with 45% of DALYs from hepatitis E (496.49 person-years). Over 11 years, 9 of the 14 NIDs showed a downward trend. Comparisons reveal that DALYs based on national surveillance data are lower than GBD 2021 estimates.
conclusionsConsiderable differences exist between the GBD estimates and national surveillance data regarding the burden of 14 NIDs in China. Therefore, strengthening national reporting systems and integrating localized data with the GBD model is essential for more accurate disease burden assessments and effective response strategies. Despite significant progress in infectious disease control, China still faces substantial challenges in domestic disease elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.